NIAID Archives
‘Pre-conditioning’ restores immune tolerance
Sep. 16, 2021—A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered.
Caught in a web: study reveals that immune cells cooperate to trap and kill bacteria
Sep. 10, 2021—Vanderbilt researchers have identified a new antibacterial mechanism that could inspire novel strategies for combating staph and other extracellular bacterial pathogens.
Study reveals missing link between high-fat diet, microbiota and heart disease
Aug. 12, 2021—A high-fat diet disrupts the biology of the gut’s inner lining and its microbial communities — and promotes the production of a metabolite that may contribute to heart disease, according to a study published Aug. 13 in the journal Science.
Establishing HIV care in Tennessee
Jul. 13, 2021—Vanderbilt researchers find that heterosexually active Black males are the least likely to establish HIV care within one month of diagnosis and suggest that targeted interventions focus on this population.
Fauci shares lessons learned during pandemic response with Vanderbilt MPH students
May. 12, 2021—Anthony Fauci, MD, chief medical adviser to President Joe Biden’s administration and director of the National Institute of Allergy and Infectious Diseases (NIAID), recently met virtually with students of Vanderbilt University School of Medicine’s Master of Public Health (MPH) program to answer questions about lessons learned during the pandemic and to share career advice.
Study finds that regulatory protein prevents signaling that triggers cell death
May. 6, 2021—A protein implicated in neurodegenerative diseases including amyotrophic lateral sclerosis prevents the activation of an innate immune response that leads to cell death, Vanderbilt researchers have discovered.
Team studies new use for pulmonary hypertension drug
Mar. 25, 2021—An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.
HIV, diabetes and immune cells in fat
Mar. 18, 2021—In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.
Key factors in HIV-1 replication
Feb. 8, 2021—HIV-1, the virus that causes AIDS, exploits inositol phosphates in T cells to aid its own assembly and maturation — suggesting that targeting inositol phosphate binding could inhibit HIV-1 replication.
Exploiting viral vulnerabilities
Dec. 10, 2020—The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.
Study details early events of inflammatory response
Dec. 10, 2020—Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.
VUMC begins study of second COVID-19 vaccine
Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.
